- Zacks•4 days ago
Kura Oncology (KURA) dosed the first patient in a phase II study on tipifarnib for the treatment of chronic myelomonocytic leukemia.
- Business Wire•13 days agoAcorda Announces 2016 AMPYRA Net Sales and 2017 Financial Guidance at J.P. Morgan Healthcare Conference
Acorda Therapeutics, Inc. reported AMPYRA® Extended Release Tablets, 10 mg net sales for the fourth quarter of 2016 of $132 million. Full-year net sales for 2016 were $493 million, an increase of approximately 13% from 2015.
- Accesswire•17 days agoPost Earnings Coverage as Strongbridge Loss Narrowed; Acquires US Rights for KEYEVIS and Announced Equity Financing
Upcoming AWS Coverage on Acorda Therapeutics LONDON, UK / ACCESSWIRE / January 5, 2017 / Active Wall St. announces its post-earnings coverage on Strongbridge Biopharma PLC (NASDAQ: SBBP ) ("Strongbridge"). ...
ACOR : Summary for Acorda Therapeutics, Inc. - Yahoo Finance
Acorda Therapeutics, Inc. (ACOR)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||20.00 x 100|
|Ask||22.85 x 100|
|Day's Range||20.70 - 21.25|
|52 Week Range||16.40 - 40.57|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-155.56|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|